{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:00:34Z","timestamp":1781780434298,"version":"3.54.5"},"reference-count":30,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.nephro.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T23:31:25Z","timestamp":1637796685000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-angiog\u00e9niques : m\u00e9canisme d\u2019action et n\u00e9phrotoxicit\u00e9"],"prefix":"10.1684","volume":"18","author":[{"given":"Emmanuelle","family":"Clou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosu","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2021.08.004_bib0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/CAD.0b013e32835004ac","article-title":"The mechanisms that regulate the localization and overexpression of VEGF receptor-2\u00a0are promising therapeutic targets in cancer biology","volume":"23","author":"Kampen","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.nephro.2021.08.004_bib0160","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0165","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Fehrenbacher","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.lpm.2007.07.007","article-title":"Renal cell carcinoma and antiangiogenic therapies","volume":"37","author":"Pouessel","year":"2008","journal-title":"Presse Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0180","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Sherwood","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0185","first-page":"527","article-title":"Anti-angiogenic therapies: from theory to practice","volume":"9\u201310","author":"Bidart","year":"2013","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.nephro.2021.08.004_bib0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nephro.2012.10.003","article-title":"Toxicit\u00e9 r\u00e9nale des anti-angiog\u00e9niques","volume":"9","author":"Vigneau","year":"2013","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2021.08.004_bib0195","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.nephro.2008.10.002","article-title":"Effets vasculaires et r\u00e9naux des m\u00e9dicaments anti-angiog\u00e9niques\u00a0: recommandations fran\u00e7aises pour la pratique (SN, SFHTA, APNET, FFCD)","volume":"4","author":"Halimi","year":"2008","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2021.08.004_bib0200","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0210","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bulcan.2016.05.005","article-title":"Renovascular effects of antiangiogenic drugs","volume":"103","author":"Deray","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.nephro.2021.08.004_bib0215","first-page":"917","article-title":"Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis","volume":"19","author":"Chen","year":"2014","journal-title":"J Buon"},{"key":"10.1016\/j.nephro.2021.08.004_bib0220","first-page":"227","article-title":"Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis","volume":"34","author":"Gampenrieder","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nephro.2021.08.004_bib0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000329933","article-title":"Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines","volume":"35","author":"Szmit","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.nephro.2021.08.004_bib0230","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bulcan.2015.09.001","article-title":"Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria","volume":"102","author":"Launay-Vacher","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.nephro.2021.08.004_bib0280","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.ejca.2015.08.002","article-title":"Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043\u00a0and 62072\u00a0trials","volume":"51","author":"Duffaud","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nephro.2021.08.004_bib0285","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1681\/ASN.2013040362","article-title":"\u03b2-arrestin-1\u00a0drives endothelin-1-mediated podocyte activation and sustains renal injury","volume":"25","author":"Buelli","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0205","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.08.004_bib0290","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2021.08.004_bib0295","doi-asserted-by":"crossref","first-page":"F1656","DOI":"10.1152\/ajprenal.00275.2009","article-title":"The balance of autocrine VEGF-A and VEGF-C determines podocyte survival","volume":"297","author":"M\u00fcller-Deile","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0150","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2\u00a0signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0235","doi-asserted-by":"crossref","first-page":"143426","DOI":"10.1155\/2014\/143426","article-title":"Anti-VEGF cancer therapy in nephrology practice","volume":"2014","author":"Izzedine","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0245","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2021.08.004_bib0240","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2021.08.004_bib0250","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","article-title":"Inhibition of the VEGF signalling pathway and glomerular disorders","volume":"30","author":"Ollero","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2021.08.004_bib0275","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0260","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2007.12.8710","article-title":"Reversible posterior leukoencephalopathy syndrome induced by sunitinib","volume":"25","author":"Mart\u00edn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.nephro.2021.08.004_bib0255","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2021.08.004_bib0270","series-title":"Prise en charge des patients adultes atteints d\u2019hypertension art\u00e9rielle essentielle. Actualisation","author":"Haute Autorit\u00e9 de sant\u00e9 (HAS).","year":"2005"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521005307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521005307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2021.08.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:57:28Z","timestamp":1741190248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521005307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1769725521005307"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2021.08.004","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-angiog\u00e9niques : m\u00e9canisme d\u2019action et n\u00e9phrotoxicit\u00e9","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}